Latest & greatest articles for Phosphodiesterase Inhibitor

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Phosphodiesterase Inhibitor or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Phosphodiesterase Inhibitor and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Phosphodiesterase Inhibitor

1. Taking a hard look at the evidence: Phosphodiesterase-5-inhibitors in erectile dysfunction

Taking a hard look at the evidence: Phosphodiesterase-5-inhibitors in erectile dysfunction Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care (...) research. www.acfp.ca October 15, 2019 (en français) Don’t miss your last chance to pipe into the PEIP conference! Registration closes Friday, October 18 th . Click here to register. Taking a hard look at the evidence: Phosphodiesterase-5- inhibitors in erectile dysfunction Clinical Question: What is the efficacy and safety of phosphodiesterase-5-inhibitors (PDE5 inhibitors) for erectile dysfunction? Bottom Line: PDE5 inhibitors increase the proportion of successful sexual intercourse attempts to ~65

2019 Tools for Practice

2. Effect of cilostazol, a phosphodiesterase-3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study

Effect of cilostazol, a phosphodiesterase-3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study To perform a prospective study to evaluate the effect of cilostazol (CTZ) compared with aspirin (acetylsalicylic acid; ASA) in Korean people with diabetes and subclinical coronary atherosclerosis.A total of 100 people with diabetes who had mild to moderate coronary atherosclerosis, assessed by coronary computed tomographic angiography (CCTA

2019 EvidenceUpdates

3. Phosphodiesterase 5 inhibitors for pulmonary hypertension. (PubMed)

Phosphodiesterase 5 inhibitors for pulmonary hypertension. Pulmonary hypertension (PH) comprises a group of complex and heterogenous conditions, characterised by elevated pulmonary artery pressure, and which left untreated leads to right-heart failure and death. PH includes World Health Organisation (WHO) Group 1 pulmonary arterial hypertension (PAH); Group 2 consists of PH due to left-heart disease (PH-LHD); Group 3 comprises PH as a result of lung diseases or hypoxia, or both; Group 4 (...) includes PH due to chronic thromboembolic occlusion of pulmonary vasculature (CTEPH), and Group 5 consists of cases of PH due to unclear and/or multifactorial mechanisms including haematological, systemic, or metabolic disorders. Phosphodiesterase type 5 (PDE5) inhibitors increase vasodilation and inhibit proliferation.To determine the efficacy of PDE5 inhibitors for pulmonary hypertension in adults and children.We performed searches of CENTRAL, MEDLINE, Embase, CINAHL, and Web of Science up to 26

2019 Cochrane

4. The effects of CPAP and phosphodiesterase type 5 inhibitors on erectile function in men with obstructive sleep apnea and erectile dysfunction: a systematic review and meta-analysis

The effects of CPAP and phosphodiesterase type 5 inhibitors on erectile function in men with obstructive sleep apnea and erectile dysfunction: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

5. Role of phosphodiesterase inhibitors in stent related symptoms: a systematic review and meta-analysis

Role of phosphodiesterase inhibitors in stent related symptoms: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

6. Efficacy and safety of phosphodiesterase 5 inhibitors in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: systematic review and meta-analysis

Efficacy and safety of phosphodiesterase 5 inhibitors in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

7. Efficacy and safety of phosphodiesterase-5 inhibitors for the treatment of erectile dysfunction after rectal excision for cancer and inflammatory bowel disease: systematic review and meta-analysis

Efficacy and safety of phosphodiesterase-5 inhibitors for the treatment of erectile dysfunction after rectal excision for cancer and inflammatory bowel disease: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

8. Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: a systematic review and meta-analysis

Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

9. Effect of prolonged treatment with phosphodiesterase-5-inhibitors on endothelial dysfunction in vascular diseases and vascular risk conditions: A systematic review analysis and meta-analysis of randomized double-blind placebo-controlled trials

Effect of prolonged treatment with phosphodiesterase-5-inhibitors on endothelial dysfunction in vascular diseases and vascular risk conditions: A systematic review analysis and meta-analysis of randomized double-blind placebo-controlled trials To challenge the argument that continuous use of phosphodiesterase-5-selective inhibitors may reduce endothelial cell dysfunction in patients with vascular diseases or vascular risk conditions.This study included systematic reviews and meta-analysis (...) of randomized double-blind placebo-controlled trials dealing with the prolonged use of phosphodiesterase-5-selective inhibitors. The risk of bias and quality of trials were assessed by the Cochrane algorithm. Fixed or random effect models, standardised mean differences and heterogeneity were estimated in the study.Systematic search for randomized double-blind placebo-controlled trials was done in PubMed, Scopus, CINAHL, Science direct and the Cochrane Library.Randomized double-blind placebo-controlled

2019 EvidenceUpdates

10. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. (Full text)

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Benign prostatic hyperplasia (BPH) refers to non-malignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha-blockers (ABs) and 5-alpha reductase inhibitors (5-ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase inhibitors (PDEIs) that so far have been used mainly to treat erectile dysfunction were introduced

2018 Cochrane

11. Effect of combination therapy of endothelin receptor antagonist and phosphodiesterase 5 inhibitor on pulmonary haemodynamics and exercise capacity in patients with pulmonary arterial hypertension: a meta-analysis

Effect of combination therapy of endothelin receptor antagonist and phosphodiesterase 5 inhibitor on pulmonary haemodynamics and exercise capacity in patients with pulmonary arterial hypertension: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated

2018 PROSPERO

12. Combination therapy of phosphodiesterase 4 inhibitors for management in stable COPD patients: a meta-analysis

Combination therapy of phosphodiesterase 4 inhibitors for management in stable COPD patients: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

13. The efficacy of the combination of alpha-blocker and Phosphodiesterase-5 inhibitor in improving the quality of life in comparison to monotherapy in patients with lower urinary tract symptoms with or without erectile dysfunction

The efficacy of the combination of alpha-blocker and Phosphodiesterase-5 inhibitor in improving the quality of life in comparison to monotherapy in patients with lower urinary tract symptoms with or without erectile dysfunction Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any

2018 PROSPERO

14. Systematic review and meta-analysis of topical application of phosphodiesterase 4 (PDE4) inhibitors in atopic dermatitis

Systematic review and meta-analysis of topical application of phosphodiesterase 4 (PDE4) inhibitors in atopic dermatitis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

15. The hemodynamic interactions of combination therapy with a-blockers and phosphodiesterase-5 inhibitors compared with monotherapy with a-blockers

The hemodynamic interactions of combination therapy with a-blockers and phosphodiesterase-5 inhibitors compared with monotherapy with a-blockers Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

16. Phosphodiesterase-5 inhibitors for premature ejaculation: a systematic review and meta-analysis.

Phosphodiesterase-5 inhibitors for premature ejaculation: a systematic review and meta-analysis.

2017 European urology focus

17. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. (PubMed)

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) is associated with cough, sputum production or dyspnoea and a reduction in lung function, quality of life and life expectancy. Apart from smoking cessation, there are no other treatments that slow lung function decline. Roflumilast and cilomilast are oral phosphodiesterase 4 (PDE4) inhibitors proposed to reduce the airway inflammation and bronchoconstriction seen in COPD (...) . This is an update of a Cochrane review first published in 2011 and updated in 2013.To evaluate the efficacy and safety of oral PDE4 inhibitors in the management of stable COPD.We identified randomised controlled trials (RCTs) from the Cochrane Airways Trials Register (date of last search October 2016). We found other trials from web-based clinical trials registers.We included RCTs if they compared oral PDE4 inhibitors with placebo in people with COPD. We allowed co-administration of standard COPD therapy.One

2017 Cochrane

18. Phosphodiesterase Type 5 Inhibitors for Penile Rehabilitation Post Radical Prostatectomy: A Review of Clinical Effectiveness and Guidelines

Phosphodiesterase Type 5 Inhibitors for Penile Rehabilitation Post Radical Prostatectomy: A Review of Clinical Effectiveness and Guidelines Phosphodiesterase Type 5 Inhibitors for Penile Rehabilitation Post Radical Prostatectomy: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Phosphodiesterase Type 5 Inhibitors for Penile Rehabilitation Post Radical Prostatectomy: A Review of Clinical Effectiveness and Guidelines Phosphodiesterase Type 5 Inhibitors (...) for Penile Rehabilitation Post Radical Prostatectomy: A Review of Clinical Effectiveness and Guidelines Published on: August 24, 2017 Project Number: RC0915-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of phosphodiesterase type 5 inhibitors (PDE-5Is) for the treatment of adults requiring penile rehabilitation post radical prostatectomy? What are the evidence-based guidelines associated with penile

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

19. Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis. (Full text)

Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis. Phosphodiesterase type 5 inhibitors (PDE5-Is) are prescribed off-label for the treatment of premature ejaculation (PE).To systematically review the evidence from randomised controlled trials (RCTs) for PDE5-Is in the management of PE.Medline and other databases were searched through September 2015. Quality of RCTs was assessed. Intravaginal ejaculatory latency time (IELT) data were pooled (...) compared with an SSRI alone. Adverse events are reported with both PDE5-Is and other agents.PDE5-Is are significantly more effective than placebo and PDE5-Is combined with an SSRI are significantly more effective than SSRIs alone at increasing IELT and improving other effectiveness outcomes; however, heterogeneity is evident across RCTs. The methodological quality of the majority of RCTs is unclear.We reviewed phosphodiesterase type 5 inhibitors (PDE5-Is) for treating premature ejaculation. We found

2017 European urology focus

20. Reply to 'Efficacy and safety of phosphodiesterase-5 inhibitors for treatment of erectile dysfunction secondary to spinal cord injury: a systemic review and meta-analysis'. (Full text)

Reply to 'Efficacy and safety of phosphodiesterase-5 inhibitors for treatment of erectile dysfunction secondary to spinal cord injury: a systemic review and meta-analysis'. 28546870 2018 11 13 2058-6124 3 2017 Spinal cord series and cases Spinal Cord Ser Cases Reply to 'Efficacy and safety of phosphodiesterase-5 inhibitors for treatment of erectile dysfunction secondary to spinal cord injury: a systemic review and meta-analysis'. 16033 10.1038/scsandc.2016.33 Pannek Jurgen J Neuro-Urologie

2017 Spinal cord series and cases